bioRxivPharmacology & Toxicology
Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation
V. T.-V. Dao, M. H. Elbatreek, S. Altenhöfer, A. I. Casas, M. P. Pachado, C. T. Neullens, U. Knaus, H. H. H. W. Schmidt
Abstract
Unphysiological reactive oxygen species (ROS) formation is considered an important pathomechanism for several disease phenotypes with high unmet medical need. Therapeutically, antioxidants have failed multiple times. Instead, focusing on only disease-relevant, enzymatic sources of ROS appears to be a more promising and highly validated approach. Here the family of five NADPH oxidases (NOX) stands out as drug targets. Validation has been restricted, however, mainly to genetically modified rodents and is lacking in other species including human. It is thus unclear whether the different NOX isoforms are sufficiently distinct to allow selective pharmacological modulation. Here we show for five of the most advanced NOX inhibitors that indeed isoform selectivity can be achieved. NOX1 was most potently (IC50) targeted by ML171 (0.1 M); NOX2, by VAS2870 (0.7 M); NOX4, by M13 (0.01 M) and NOX5, by ML090 (0.01 M). Conditions need to be carefully controlled though as previously unrecognized non-specific antioxidant and assay artefacts may limit the interpretation of data and this included, surprisingly, one of the most advanced NOX inhibitors, GKT136901. As proof-of-principle that now also pharmacological and non-rodent target validation of different NOX isoforms is possible, we used a human blood-brain barrier model and NOX inhibitor panel at IC50 concentrations. The protective efficacy pattern of this panel confirmed the predominant role of NOX4 in stroke from previous genetic models. Our findings strongly encourage further lead optimization efforts for isoform-selective NOX inhibitors and clinical development and provide an experimental alternative when genetic validation of a NOX isoform is not an option.\n\nO_FIG O_LINKSMALLFIG WIDTH=193 HEIGHT=200 SRC=\"FIGDIR/small/382226v2_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (26K):\norg.highwire.dtl.DTLVardef@1708996org.highwire.dtl.DTLVardef@15909daorg.highwire.dtl.DTLVardef@960159org.highwire.dtl.DTLVardef@328083_HPS_FORMAT_FIGEXP M_FIG Graphical abstract C_FIG
- organism: human
- research focus: drug response / drug discovery
- research focus: cell type annotation
- research focus: differential expression
- research focus: protein folding & dynamics
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Calcium-dependent reactive oxygen formation and blood-brain barrier breakdown by NOX5 limits post-reperfusion outcome in stroke
Ana Isabel Casas, Pamela W. M. Kleikers, … Harald H.H.W. Schmidt·bioRxiv·Jun 30, 2018
- X-Ray Structure and enzymatic study of a Bacterial NADPHoxidase highlight the activation mechanism of eukaryoticNOX
I. Petit-Hartlein, A. Vermot, … F. Fieschi·bioRxiv·Oct 16, 2023
- Neuronal NADPH oxidase in Parkinson disease pathogenesis
Matthew T. Keeney, Eric K. Hoffman, … Roberto Di Maio·bioRxiv·May 13, 2021
- NADPH oxidase 4-derived hydrogen peroxide counterbalances testosterone-induced endothelial dysfunction and migration
J. V. Alves, R. M. Costa, … T. Bruder-Nascimento·bioRxiv·Aug 30, 2023
- NADPH oxidase inhibitor enhances brain resilience in Alzheimer's disease by reducing tauopathy and neuroinflammation
Jihyeon Lee, Seunghwan Sim, … Yun Soo Bae·bioRxiv·Mar 1, 2025
- Cooperation between CYB5R3 and NOX4 via coenzyme Q mitigates endothelial inflammation
S. Yuan, S. Hahn, … A. C. Straub·Redox BiologyPeer-reviewed·Nov 1, 2021